Economic sustainability of immune-checkpoint inhibitors: the looming threat

被引：18
作者：
Verma, Vivek [1 ]
机构：
[1] Allegheny Gen Hosp, Dept Radiat Oncol, Pittsburgh, PA 15212 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2018年 / 15卷 / 12期
关键词：
COST-EFFECTIVENESS ANALYSIS; SQUAMOUS-CELL CARCINOMA; NIVOLUMAB; RECURRENT; PEMBROLIZUMAB; DOCETAXEL; HEAD;
D O I：
10.1038/s41571-018-0086-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immune-checkpoint inhibitors (ICIs) are transforming oncology, but the mounting costs of cancer care necessitate concerns regarding economic sustainability. Here, several strategies that clinicians could use to exercise economically prudent administration of ICIs are discussed. These include better appraisal of the cost-effectiveness literature, judicious patient selection, separating statistical from clinical significance, and careful patient counselling.
引用
收藏
页码：721 / 722
页数：2
相关论文
共 10 条
  • [1] The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
    Aguiar, P. N., Jr.
    Perry, L. A.
    Penny-Dimri, J.
    Babiker, H.
    Tadokoro, H.
    de Mello, R. A.
    Lopes, G. L., Jr.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (09) : 2256 - 2263
  • [2] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426
  • [3] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
    Ferris, R. L.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Iglesias Docampo, L. C.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Monga, M.
    Lynch, M.
    Geese, W. J.
    Kopit, J.
    Shaw, J. W.
    Gillison, M. L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1856 - 1867
  • [4] Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
    Huang, Min
    Lou, Yanyan
    Pellissier, James
    Burke, Thomas
    Liu, Frank Xiaoqing
    Xu, Ruifeng
    Velcheti, Vamsidhar
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) : 140 - 150
  • [5] Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
    Lopes, Gilberto
    Wu, Yi-Long
    Kudaba, Iveta
    Kowalski, Dariusz
    Cho, Byoung Chul
    Castro, Gilberto
    Srimuninnimit, Vichien
    Bondarenko, Igor
    Kubota, Kaoru
    Lubiniecki, Gregory M.
    Zhang, Jin
    Kush, Debra A.
    Mok, Tony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [6] Projections of the Cost of Cancer Care in the United States: 2010-2020
    Mariotto, Angela B.
    Yabroff, K. Robin
    Shao, Yongwu
    Feuer, Eric J.
    Brown, Martin L.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (02): : 117 - 128
  • [7] A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Aebi, Stefan
    Dedes, Konstantin
    Diebold, Joachim
    Pietrini, Mario
    Klingbiel, Dirk
    von Moos, Roger
    Gautschi, Oliver
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : 1846 - 1855
  • [8] Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
    McCrea, Charles
    Johal, Sukhvinder
    Yang, Shuo
    Doan, Justin
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [9] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leiby, Melanie A.
    Lubiniecki, Gregory M.
    Shentu, Yue
    Rangwala, Reshma
    Brahmer, Julie R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1823 - 1833
  • [10] Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Tringale, Kathryn R.
    Carroll, Kate T.
    Zakeri, Kaveh
    Sacco, Assuntina G.
    Barnachea, Linda
    Murphy, James D.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05): : 479 - 485
1